Open access
Open access
Powered by Google Translator Translator

Oncology – Lung

M-A | Sensitivity and complications of thoracentesis and thoracoscopy for the diagnosis of malignant pleural effusions

27 Jan, 2023 | 12:11h | UTC

Sensitivity and complications of thoracentesis and thoracoscopy: a meta-analysis – European Respiratory Review

 


Review | Lung cancer screening: new evidence, updated guidance

26 Jan, 2023 | 12:08h | UTC

Lung cancer screening: New evidence, updated guidance – Journal of Family Practice

 


Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Guideline for diagnosis, treatment and follow-up

23 Jan, 2023 | 13:32h | UTC

Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up – Annals of Oncology

 


Post-trial follow-up | Efficacy and safety of first-line lorlatinib vs. crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer

19 Jan, 2023 | 13:49h | UTC

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

Original Study: First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer – New England Journal of Medicine

 

Commentary on Twitter

 


A deep learning model may predict future lung cancer risk from a single low-dose chest CT

18 Jan, 2023 | 14:00h | UTC

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography – Journal of Clinical Oncology

News Release: Artificial intelligence tool developed to predict risk of lung cancer – Massachusetts General Hospital

Commentary: AI tool predicts lung cancer without radiologists or clinical histories – Health Imaging

 


RCT | High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer

15 Jan, 2023 | 19:51h | UTC

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer without driver alterations

12 Jan, 2023 | 13:12h | UTC

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2 – Journal of Clinical Oncology

Editorial: ASCO Living Guidelines: The Next Frontier

Commentary: ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreak100, Other Trials – ASCO Daily News

 


ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer with driver alterations

12 Jan, 2023 | 13:13h | UTC

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2 – Journal of Clinical Oncology

Editorial: ASCO Living Guidelines: The Next Frontier

Commentary: ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreak100, Other Trials – ASCO Daily News

 


RCT | Durvalumab with or without Tremelimumab plus chemotherapy for metastatic non–small-cell lung cancer.

14 Dec, 2022 | 14:47h | UTC

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study – Journal of Clinical Oncology

Commentary: Adding Tremelimumab and Durvalumab to Chemo Improves PFS, OS in mNSCLC – Cancer Therapy Advisor

 

Commentary on Twitter

 


Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.

3 Nov, 2022 | 13:39h | UTC

Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)

Commentaries:

Sinoatrial Node Radiation During CRT May Increase Risk of Atrial Fibrillation in SCLC and NSCLC – Cancer Network

Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News

 

Commentary on Twitter

 


NICE Guideline Update | Lung cancer: diagnosis and management.

2 Nov, 2022 | 14:28h | UTC

Lung cancer: diagnosis and management – National Institute for Health and Care Excellence

 


Post-trial follow-up | Pembrolizumab vs. chemotherapy as first-line therapy in PD-L1-expressing non–small-cell lung cancer.

31 Oct, 2022 | 13:39h | UTC

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study – Journal of Clinical Oncology

Original Study: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial – The Lancet

 


RCT | Lurbinectedin plus Doxorubicin are no better than physician’s choice of chemotherapy in relapsed small-cell lung cancer.

20 Oct, 2022 | 12:19h | UTC

Combination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Post-trial follow-up | Nivolumab plus ipilimumab vs. chemotherapy as first-line treatment for metastatic non-small cell lung cancer.

19 Oct, 2022 | 14:17h | UTC

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227 – Journal of Clinical Oncology (link to abstract – $ for full-text)

Original Study: #ESMO19 –Randomized Trial: Improved Overall Survival with Combined Immunotherapy for Advanced Non–Small-Cell Lung Cancer

 


RCT | Toripalimab plus chemotherapy for patients with treatment-naive advanced non–small-cell lung cancer.

11 Oct, 2022 | 13:31h | UTC

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) – Journal of Clinical Oncology

Commentary: CHOICE-01: Toripalimab Plus Chemotherapy Improves Survival in Advanced NSCLC Without Actionable Mutations – The ASCO Post

 


RCT | Pembrolizumab vs. placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer.

29 Sep, 2022 | 13:22h | UTC

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC – The ASCO Post

Adjuvant Pembrolizumab Prolongs DFS in Resected Non-Small Cell Lung Cancer – Cancer Therapy Advisor

 

Commentary on Twitter

 


RCT | First-Line Serplulimab vs. placebo added to chemotherapy in patients with extensive-stage small cell lung cancer.

28 Sep, 2022 | 13:41h | UTC

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual Abstract

 


RCT | Efficacy and safety of carboplatin with nab-paclitaxel vs. docetaxel in older patients with squamous non-small-cell lung cancer.

14 Sep, 2022 | 13:00h | UTC

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial – The Lancet Health Longevity

 

Commentary on Twitter

 


RCT | Dexamethasone is not effective for the treatment of dyspnea in patients with cancer and increases the risk of adverse events.

13 Sep, 2022 | 13:22h | UTC

Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial – The Lancet Oncology (free for a limited period)

 

Commentary on Twitter

 


RCT | Anatomical segmentectomy vs. standard lobectomy for non-small cell lung cancer up to 2 cm.

6 Sep, 2022 | 14:28h | UTC

Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm – Lung Cancer

Related:

A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation.

Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)

A Meta-Analysis Comparing Lobectomy versus Segmentectomy in Stage I Non-Small Cell Lung Cancer – The Korean Journal of Thoracic and Cardiovascular Surgery

 


RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.

29 Aug, 2022 | 12:08h | UTC

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial – Nature Medicine

 

Commentary on Twitter

 


RCT | Nivolumab vs. nivolumab plus docetaxel for previously treated advanced or recurrent immune checkpoint inhibitor-naïve non-small-cell lung cancer.

25 Aug, 2022 | 11:48h | UTC

A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630 – Clinical Cancer Research

 


M-A | Erlotinib plus bevacizumab vs. erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer.

22 Aug, 2022 | 12:04h | UTC

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials – BMJ Open

 


RCT | Chest CT scan plus x-ray vs. chest x-ray for the follow-up of completely resected non-small-cell lung cancer.

16 Aug, 2022 | 13:50h | UTC

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 


Long-term results of a RCT | Gefitinib-alone vs. Gefitinib plus chemotherapy for non–small-cell lung cancer with mutated EGFR.

15 Aug, 2022 | 11:44h | UTC

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR – Journal of Clinical Oncology

Original Study: Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study – Journal of Clinical Oncology

 


Stay Updated in Your Specialty

No spam, just news.